Sprouts Farmers Market closes $600 million revolving credit facility
WALTHAM, Mass. - Revvity, Inc. (NYSE:RVTY) reported better-than-expected first quarter results on Monday.
The company’s shares were up 4.46% in premarket trading following the release.
The health science solutions provider posted adjusted earnings per share of $1.01, surpassing analyst estimates of $0.95. Revenue came in at $665 million, topping the consensus forecast of $661.92 million and representing 2% year-over-year growth.
"Revvity navigated a dynamic environment and delivered strong first quarter results," said CEO Prahlad Singh. "Our strong execution combined with the uniqueness of our businesses drove our revenue, earnings and cash flow to each exceed our expectations in the quarter."
The company’s Life Sciences segment saw revenue increase 1% to $340 million, while Diagnostics revenue rose 3% to $324 million. On an organic basis, excluding currency impacts, Life Sciences and Diagnostics grew 2% and 5% respectively.
For the full year 2025, Revvity reaffirmed its adjusted EPS guidance of $4.90-$5.00 and organic revenue growth forecast of 3-5%. The company raised its total revenue outlook to $2.83-$2.87 billion to reflect recent foreign exchange movements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.